Advertisement

The Role of Chemotherapy in the Treatment of Bone and Soft-tissue Sarcomas

  • Dennis Priebat
  • Martin Malawer
Chapter

Overview

Sarcomas are rare, mesenchymal tumors of the soft tissue and bone that exhibit a marked heterogeneity in their clinical presentation, biologic behavior, and histologic features. Approximately 10,400 new cases are diagnosed annually, 7800 of which arise from the soft tissues (50–60% of which involve the extremities) and 2600 from bones.1 Although the incidence of extremity sarcomas is similar to that of Hodgkin’s disease, they are responsible for more than twice as many deaths each year. Major advances in the treatment of these tumors have been limited by an inability to accumulate sufficient numbers of similar patients to perform prospective randomized clinical trials with results that can achieve statistical significance.

Until the 1970s, surgery and/or radiation therapy was the accepted method for the primary management of most soft-tissue and bone sarcomas of the extremities. However, surgery alone, especially wide resection, was associated with a high incidence of local recurrences. Even when local control was achieved, more than 50% of patients with soft-tissue sarcoma and 80% of patients with skeletal sarcoma (osteogenic and Ewing’s sarcoma) eventually developed distant metastases and died, usually within 2 years.2–11 Systemic chemotherapy was subsequently found to exhibit reproducible anti-tumor effects against these neoplasms. Initially used only in the treatment of metastatic disease, this was later used as a part of combined-modality therapy in the adjuvant (postoperative) setting, and then as preoperative (neoadjuvant, induction) therapy in an attempt to preserve limb function and/or increase long-term survival.2–11 The routes of chemotherapy administration have included intravenous (IV) bolus, continuous IV infusion, and local (regional) drug delivery directly to the tumor via a feeding artery.12

Keywords

Adjuvant Chemotherapy Clin Oncol Soft Tissue Sarcoma Induction Chemotherapy National Comprehensive Cancer Network 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. CA Canc J Clin. 1999;49:12–13.Google Scholar
  2. 2.
    Malawer MM, Henshaw RM, Shmookler BM. Principles of orthopedic onoclogy. In: Lee R, Hurst LC, Gruber MA, Kottmeier SA, editors. Principles of Orthopedic Practice. New York: McGraw-Hill; 1997;225–71.Google Scholar
  3. 3.
    Brennan MF, Casper ES, Harrison LB. Soft tissue sarcoma. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997;1738–88.Google Scholar
  4. 4.
    Bierman JS, Baker LH. The future of sarcoma treatment. Sem Oncol. 1997;24:592–7.Google Scholar
  5. 5.
    Demetri GD, Pollock R. National Comprehensive Cancer Network (NCCN) Sarcoma Practice Guidelines, Version 97-1.0. Oncology. 1998;12:183–218.PubMedGoogle Scholar
  6. 6.
    Malawer M, Link MP, Donaldson SS. Sarcomas of bone. In: Devita V, Hellman S, Rosenberg S, editors. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott-Raven; 1997;1789–1852.Google Scholar
  7. 7.
    Link MP, Eilber F. Osteosarcoma. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Raven; 1997;889–920.Google Scholar
  8. 8.
    Bramwell VHC. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol. 1997;24:561–71.PubMedGoogle Scholar
  9. 9.
    Meyers PA, Gorlick R: Osteosarcoma. Pediatr Clin N Am. 1997;44:973–89.Google Scholar
  10. 10.
    Dome JS, Schwartz CL. Osteosarcomas. Cancer Treat Res. 1997;92:215–51.PubMedGoogle Scholar
  11. 11.
    Horowitz ME, Malawer MM, Woo SY, Hicks MJ. Ewing’s sarcoma family of tumors: Ewing’s sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology, 3rd edn. Philadelphia: Lippincott-Raven; 1997;831–63.Google Scholar
  12. 12.
    Priebat DA, Trehan PS, Malawer MM, Schulof RS. Induction chemotherapy for sarcomas of the extremities. In: Sugarbaker PH, Malawer MM, editors. Musculoskeletal Surgery for Cancer. New York: Thieme; 1992:96–120.Google Scholar
  13. 13.
    Pisters PWT, Feig BW, Leong DHY, Brennan MF. New developments in soft tissue sarcoma. In: Pollock RE, editor. Surgical Oncology. Lancaster: Kluwer; 1997;91–107.Google Scholar
  14. 14.
    Yasko AW, Reece GP, Gillis TA, Pollock RE. Limb salvage strategies to optimize quality of life, the M.D. Anderson Cancer Center Experience. Cancer J Clin 1997;47:226–38.Google Scholar
  15. 15.
    O’Byrne K, Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology. 1999;56:13–23.PubMedGoogle Scholar
  16. 16.
    O’Brian RM, Baker LH, Gottlieb JE et al. Dose response evaluation of Adriamycin in human neoplasia. Cancer. 1977;39:1940–8.Google Scholar
  17. 17.
    Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol/Oncol Clin N Am. 1995;9:765–85.Google Scholar
  18. 18.
    Keohan ML, Taub RN. Chemotherapy for advanced sarcoma: therapeutic decisions and modalities. Semin Oncol. 1997;24:572–9.PubMedGoogle Scholar
  19. 19.
    Zalupski M, Metch B, Balcerzak S et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft tissue sarcomas: a SWOG study. J Natl Cancer Inst. 1991;83:927–32.Google Scholar
  20. 20.
    Casper ES, Gaynor JJ, Hajdu SI et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68:1221–9.PubMedGoogle Scholar
  21. 21.
    Dombernowsky P, Mouridsen H, Nielsen OS et al. A phase III study comparing Adriamycin versus two schedules of high dose epirubicin in advanced soft tissue sarcoma. Proc Am Soc Clin Oncol. 1995;14:1688a.Google Scholar
  22. 22.
    Elson P, Chidiac T, Budd GT et al. Phase II trial of doxil in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol. 1998;17:1979a.Google Scholar
  23. 23.
    Bramwell VHC, Mouridsen HT, Santoro A et al. Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23:311–21.CrossRefPubMedGoogle Scholar
  24. 24.
    Demetri GD. High dose ifosfamide in the treatment of sarcomas of soft tissues and bone. Semin Oncol. 1996; 23(Suppl. 6):22–6.PubMedGoogle Scholar
  25. 25.
    Benjamin RS, Legha SS, Patel SR et al. Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience. Cancer Chemother Pharmacol. 1993;31(Suppl. 2):S174–9.Google Scholar
  26. 26.
    Patel SR, Vadhan-Raj S, Papadopolous N et al. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies — dose response and schedule dependence. J Clin Oncol. 1997;15:2378–84.PubMedGoogle Scholar
  27. 27.
    Rosen G, Forscher C, Lowenbraun S et al. Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506–11.PubMedGoogle Scholar
  28. 28.
    Le Cesne A, Spielmann AM, Le Chevalier T et al. High dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol. 1995;13:1600–8.PubMedGoogle Scholar
  29. 29.
    Antman KH, Ryan L, Elias A et al. Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol. 1989;7: 126–31.PubMedGoogle Scholar
  30. 30.
    Van Oosterom AT, Krzemienlecki K, Nielson OS et al. Final results of a randomized phase II study of the EORTC Soft Tissue and Bone Sarcoma (STSBS) Group comparing two different ifosfamide regimens in chemotherapy untreated advanced soft tissue sarcoma patients. Ann Oncol. 1998; 9:115a.Google Scholar
  31. 31.
    Nielson OS, Judson I, Van Hoesel Q et al. Effect of high dose ifosfamide in advanced soft tissue sarcomas. A multicenter phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Proc Am Soc Clin Oncol. 1998;17: 1992a.Google Scholar
  32. 32.
    Kupfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 1994;343:763–4.CrossRefPubMedGoogle Scholar
  33. 33.
    Wengs WJ, Talwar D, Bernard J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol. 1993;50: 1104–5.PubMedGoogle Scholar
  34. 34.
    Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;35:249–52.Google Scholar
  35. 35.
    Steward WP, Verweij J, Somers R et al. Granulocytemacrophage colony stimulating factor allows a safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1993;11:15–21.PubMedGoogle Scholar
  36. 36.
    Rosen G, Chawla S, Hamburg S, Lowenbraun S. Phase II study of high dose continuous infusion dimethyl triazeno imidazole carboxamide (DTIC) in metastatic leiomyosarcoma. Proc Am Soc Clin Oncol. 1990;9:313.Google Scholar
  37. 37.
    Van Hoesel OGCM, Verweij J, Catimel G et al. Phase II study with docetaxel (taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol. 1994;5:539–42.PubMedGoogle Scholar
  38. 38.
    Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas: a SWOG study. Cancer. 1995;76:2248–52.PubMedGoogle Scholar
  39. 39.
    Jelic S, Koucin V, Milanovic N et al. Randomized study of high-dose epirubicin versus high-dose epirubicincisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer. 1997;33:220–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Spath-Schwalbe E, Koschuth A, Grunewald R et al. Gemcitabine in pretreated patients with advanced soft tissue sarcomas — preliminary results from a phase II trial. Proc Am Soc Clin Oncol. 1998;17:1976a.Google Scholar
  41. 41.
    Seynaeve C, Verweij J. High-dose chemotherapy in adult sarcomas: no standard yet. Semin Oncol. 1999;26:119–33.PubMedGoogle Scholar
  42. 42.
    Santoro A. Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? Ann Oncol. 1999;10:151–4.PubMedGoogle Scholar
  43. 43.
    Elias A, Ryan L, Sulkes A et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol. 1989;7:1208–16.PubMedGoogle Scholar
  44. 44.
    Antman K, Crowley J, Balcerzak S et al. An intergroup (SWOG and CALGB) phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11:1276–85.PubMedGoogle Scholar
  45. 45.
    Edmondson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993;11:1269–75.Google Scholar
  46. 46.
    Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first line treatment of advanced soft tissue sarcomas. A randomized study of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1995;13:1537–45.PubMedGoogle Scholar
  47. 47.
    Patel SR, Vadjan-Raj S, Burgess MA et al. Results of two consecutive trials of dose intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol. 1998;21:317–21.PubMedGoogle Scholar
  48. 48.
    Patel SR, Benjamin RS. New chemotherapeutic strategies for soft tissue sarcomas. Semin Surg Oncol. 1999;17: 47–51.CrossRefPubMedGoogle Scholar
  49. 49.
    Bokemeyer C, Franzke A, Hartmann JT et al. A phase I/II study of sequential dose escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer. 1997;80:1221–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Reichardt P, Tilgner J, Hohenberger P, Dorken B. Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgastrin for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998;16:1438–43.PubMedGoogle Scholar
  51. 51.
    Tursz T, Verweij J, Judson I et al. Is high-dose chemotherapy of interest in advanced soft tissue sarcomas? An EORTC randomized phase III trial. Proc Am Soc Clin Oncol. 1996;15:973a.Google Scholar
  52. 52.
    Mazaneth R, Antman KH. Sarcomas of soft tissue and bone. Cancer. 1991;68:463–73.Google Scholar
  53. 53.
    Zalupski MM, Baker LH. Systemic adjuvant chemotherapy for soft tissue sarcomas. Hematol/Oncol Clin N Am. 1995;9:787–800Google Scholar
  54. 54.
    Lewis JJ, Benedetti F. Adjuvant therapy for soft tissue sarcomas. Surg Oncol Clin N Am. 1997;6:847–62.PubMedGoogle Scholar
  55. 55.
    Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin Oncol. 1997;24:556–60.PubMedGoogle Scholar
  56. 56.
    Tierney JF (Sarcoma Meta-Analysis Collaboration). Adjuvant chemotherapy for localized unresectable soft tissue sarcoma of adults: meta-analysis of individualized data. Lancet. 1997;350:1647–54.Google Scholar
  57. 57.
    Chang AE, Kinsella T, Glatstein E et al. Adjuvant chemotherapy for patients with high grade soft tissue sarcomas of the extremity. J Clin Oncol. 1988;6:1491–1500.PubMedGoogle Scholar
  58. 58.
    Gherlinzoni F, Picci P, Bacci G et al. Late results of a randomized trial for the treatment of soft tissue sarcomas (STS) of the extremities in adult patients. Proc Am Soc Clin Oncol. 1993;12:1633a.Google Scholar
  59. 59.
    Bramwell V, Rouesse J, Steward W et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12:1137–49.PubMedGoogle Scholar
  60. 60.
    Frustaci S, Gherlinzoni A, DePaoli G et al. Preliminary results of an adjuvant randomized trial on high risk extremity soft tissue sarcoma. The interim analysis. Proc Am Soc Clin Oncol. 1997;16:1785a.Google Scholar
  61. 61.
    Picci P, Frustaci S, DePaoli G et al. Localized high-grade soft tissue sarcomas of the extremities in adults: preliminary results of the Italian Cooperative study. Sarcoma. 1997;1:CTOS abstract 197.Google Scholar
  62. 62.
    Eilber FR, Eckhardt J. Surgical management of soft tissue sarcomas. Semin Oncol. 1997;24:526–33.PubMedGoogle Scholar
  63. 63.
    Singer S, Eberlein TJ. Surgical management of soft tissue sarcoma. In: Advances in Surgery. 1998;31:395–420.Google Scholar
  64. 64.
    Eilber FR, Eckhardt JF, Rosen G et al. Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft tissue sarcomas of the extremity. Surg Oncol Clin N Am. 1993;2:611–20.Google Scholar
  65. 65.
    Koops HS, Eggermont AMM, Lienard D et al. Hyperthermic isolated limb perfusion for the treatment of soft tissue sarcomas. Semin Surg Oncol. 1998;14:210–14.CrossRefGoogle Scholar
  66. 66.
    Pezzi CM, Pollock RE, Evans HL et al. Preoperative chemotherapy for soft tissue sarcoma of the extremities. Ann Surg. 1990;211:476–81.PubMedGoogle Scholar
  67. 67.
    Casper ES, Gaynor JJ, Harrison LB et al. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma. Cancer. 1994;73:1644–51.PubMedGoogle Scholar
  68. 68.
    Pisters PWT, Patel SR, Varma DGK et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol. 1997;15:3481–7.PubMedGoogle Scholar
  69. 69.
    Eilber F, Eckhardt J, Rosen G et al. Improved complete response rate with neoadjuvant chemotherapy and radiation for high grade extremity soft tissue sarcomas. Proc Am Soc Clin Oncol. 1994;13:1645a.Google Scholar
  70. 70.
    Eilber F, Eckhardt J, Rosen G. Preoperative therapy for soft tissue sarcomas. Hematol/Oncol Clin N Am. 1995;9:3:817–23.Google Scholar
  71. 71.
    Spiro IJ. Suit H, Gebhardt M et al. Neoadjuvant chemotherapy and radiotherapy for large soft tissue sarcomas. Proc Am Soc Clin Oncol. 1996;15:1689a.Google Scholar
  72. 72.
    Priebat D, Malawer M, Markan Y et al. Clinical outcome of neoadjuvant intraarterial cisplatin and continuous intravenous infusion Adriamycin for large high grade unresectable/borderline soft tissue sarcomas of the extremities. Proc Am Soc Clin Oncol. 1994;13:1648a.Google Scholar
  73. 73.
    Henshaw R, Valente A, Shmookler BM, Priebat D, Malawer MM. Limb salvage, histologic necrosis and disease free survival for unresectable soft tissue sarcomas treated with neoadjuvant intraarterial chemotherapy and attempted surgical resection. Am Acad Orthop Surg. 1997;64:180a.Google Scholar
  74. 74.
    Gutman M, Inbar M, Lev-Shlush D et al. High dose tumor necrosis factor α and melphalan via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79:1129–37.CrossRefPubMedGoogle Scholar
  75. 75.
    Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972;4:482–510.PubMedGoogle Scholar
  76. 76.
    Goorin AM, Abelson HT, Frei E III. Osteosarcoma: Fifteen years later. N Engl J Med. 1985;313:1637–43.PubMedGoogle Scholar
  77. 77.
    Smith MA, Ungerleider RS, Horowitz ME et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing’s sarcoma. J Natl Cancer Inst. 1991;83:1460–70.PubMedGoogle Scholar
  78. 78.
    Grem JL, King SA, Wittes RE et al. The role of methotrexate in osteosarcoma. J Natl Cancer Inst. 1988;80:626–55.PubMedGoogle Scholar
  79. 79.
    Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep. 1982;66:1687–97.PubMedGoogle Scholar
  80. 80.
    Saeter G, Alvegard TA, Elomaa I et al. Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study. J Clin Oncol. 1991;9: 1766–75.PubMedGoogle Scholar
  81. 81.
    Ferrari S, Sassoli V, Orlandi M et al. Serum methotrexate concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multi-drug neoadjuvant regimen. J Chemother. 1993;5:135–41.PubMedGoogle Scholar
  82. 82.
    Graf N, Winkler K, Betlemovic M et al. Methotrexate pharmokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994;12:1443–51.PubMedGoogle Scholar
  83. 83.
    Delepine N, Delepine G, Bacci G et al. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic sarcoma: analysis of the literature. Cancer. 1996;78:2127–35.CrossRefPubMedGoogle Scholar
  84. 84.
    Bielack SS, Beron G, Winkler K. Influence of methotrexate dose intensity on outcome of patients with high grade osteogenic osteosarcoma: analysis of the literature. Delepine H et al. Author reply. Cancer. 1997;80:516–18.CrossRefPubMedGoogle Scholar
  85. 85.
    Bacci G, Ferrari S, Delepine N et al. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol. 1998;16:658–62.PubMedGoogle Scholar
  86. 86.
    Ochs J, Freeman A, Douglas H et al. Cis-dichloro-diammine platinum in advanced osteogenic sarcoma. Cancer Treat Rep. 1978;62:239–45.PubMedGoogle Scholar
  87. 87.
    Marti C, Kroner T, Remagen W et al. High dose ifosfamide in advanced osteogenic sarcoma. Cancer Treat Res. 1985; 69:115–17.Google Scholar
  88. 88.
    Chawla SP, Rosen G, Lowenbraun S et al. Role of high dose ifosfamide in recurrent osteosarcoma. Proc Am Soc Clin Oncol. 1990;9:310.Google Scholar
  89. 89.
    Harris MB, Cantor AB, Goorin AM et al. Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated. A Pediatric Oncology Group Study. Med Ped Oncol. 1995;24:87–92.Google Scholar
  90. 90.
    Rosen G, Forscher CA, Eilber F, Eckhardt J. Guidelines for chemotherapy of osteosarcoma. Second Osteosarcoma Research Conference, Bologna, Italy, 19–22 November 1996:5.Google Scholar
  91. 91.
    Ham SJ, Schraffordt Koops H, van der Graaf WTA et al. Historical, current, and future aspects of osteosarcoma treatment. Eur J Surg Oncol. 1998;24:584–600.PubMedGoogle Scholar
  92. 92.
    Guo W, Healey JH, Meyers PA et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 1999;5:621–7.PubMedGoogle Scholar
  93. 93.
    Petrilli S, Silva N, Luisi E et al. Pediatric osteosarcoma of extremities: initial intraarterial therapy with carboplatin as single agent for patients previously untreated. Proc Am Soc Clin Oncol. 1993;12:A1482.Google Scholar
  94. 94.
    Ferguson W, Harris M, Link M et al. Carboplatin in the treatment of newly diagnosed metastatic or unresectable osteosarcoma: a Pediatric Oncology Group study. Proc Am Soc Clin Oncol. 1996;15:A1678.Google Scholar
  95. 95.
    Meyer WH, Pratt CB, Rao BN et al. Curative therapy for osteosarcoma without cisplatinum — preliminary results of SJCRH OS-91. Proc Am Soc Clin Oncol. 1997;16:A1842.Google Scholar
  96. 96.
    Pratt CB, Epelman S, Jaffe N. Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: lack of tumor regression in previously treated patients. Cancer Treat Rep. 1987;7:421–3.Google Scholar
  97. 97.
    Souhami RL, Craft AW, Van der Eijken et al. Randomized trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911–17.CrossRefPubMedGoogle Scholar
  98. 98.
    Ornadel D, Souhami RL, Whelan J et al. Doxorubicin and cisplatinum with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma. Phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol. 1994;12:1842–8.PubMedGoogle Scholar
  99. 99.
    Bramwell VHC. The role of chemotherapy in osteogenic sarcoma. Crit Rev Oncol/Hematol. 1995;20:61–85.Google Scholar
  100. 100.
    Eilber FR, Rosen G. Adjuvant chemotherapy for osteosarcoma. Semin Oncol. 1989;16:312–23.PubMedGoogle Scholar
  101. 101.
    Carter SK. Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn’t? J Clin Oncol. 1984;2: 147–8.PubMedGoogle Scholar
  102. 102.
    Taylor WF, Ivins JC, Pritchard DI et al. Trends and variability in survival among patients with osteosarcoma. A 7-year update. Mayo Clin Proc. 1985;60:91–104.PubMedGoogle Scholar
  103. 103.
    Goorin AM, Delorey M, Gelber RE et al. Dana Farber Institute/the Children’s Hospital adjuvant chemotherapy trials for osteosarcoma: three sequential studies. Cancer Treat Symp. 1985;3:155–9.Google Scholar
  104. 104.
    Bacci G, Gherlinzoni F, Picci P et al. Adriamycin methotrexate high dose versus adriamycin methotrexate moderate dose as adjuvant chemotherapy for osteosarcoma of the extremities. A randomized study. Eur J Clin Oncol. 1986;22:1337–45.CrossRefGoogle Scholar
  105. 105.
    Ettinger LJ, Douglas HO, Mindell ER et al. Adjuvant Adriamycin and cisplatinum in newly diagnosed non-metastatic osteosarcoma of the extremity. J Clin Oncol. 1986;4:352–62.Google Scholar
  106. 106.
    Pratt CB, Champion JE, Fleming ID et al. Adjuvant chemotherapy for osteosarcoma of the extremity: long term results of two consecutive prospective protocol studies. Cancer. 1990;65:439–45.PubMedGoogle Scholar
  107. 107.
    Link MP Goorin AM, Miser AW et al The effect of adjuvant chemotherapy on relapse free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600–6.PubMedGoogle Scholar
  108. 108.
    Link MP, Goorin AM, Horowitz M et al. Adjuvant chemotherapy of high grade osteosarcoma of the extremity: updated results of the multi-institutional osteosarcoma study. Clin Orthop Rel Res. 1991;270:8–14.Google Scholar
  109. 109.
    Eilber F, Giuliano A, Eckhardt J et al. Adjuvant chemotherapy for osteosarcoma. A randomized prospective trial. J Clin Oncol. 1987;5:21–26.PubMedGoogle Scholar
  110. 110.
    Jaffe N, Smith E, Abelson HT et al. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol. 1983;1:251–4.PubMedGoogle Scholar
  111. 111.
    Goorin AM, Schuster JJ, Baker A et al. Changing pattern of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: results from the Multi-Institutional Osteosarcoma Study. J Clin Oncol. 1991;9: 600–5.PubMedGoogle Scholar
  112. 112.
    Giuliano AE, Feig S, Eilber F. Changing metastatic patterns of osteosarcoma. Cancer. 1984;54:2160–4.PubMedGoogle Scholar
  113. 113.
    Huth JF, Eilber FR. Patterns of recurrence after resection of osteosarcoma of the extremity. Strategies for treatment of metastases. Arch Surg. 1989; 124:122–6.PubMedGoogle Scholar
  114. 114.
    Tabone MD, Kalifa C, Rodary C et al. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol. 1994;12:2614–20.PubMedGoogle Scholar
  115. 115.
    Saeter G, Hoie J, Stenwig AE et al. Systemic relapse of patients with osteogenic sarcoma: prognostic factors for long term survival. Cancer. 1995;75:1084–93.PubMedGoogle Scholar
  116. 116.
    Rosen G, Marcove RC, Caparros B. Primary osteosarcoma. The rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163–77.PubMedGoogle Scholar
  117. 117.
    Bacci G, Springfield D, Capanna R et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity. Clin Orthop. 1987;224:268–76.PubMedGoogle Scholar
  118. 118.
    Winkler K, Beron G, Delling G et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329–37.PubMedGoogle Scholar
  119. 119.
    Gherlinzoni M, Mercuri M, Avella M et al. Surgical implications of neoadjuvant chemotherapy: the experience at the Instituto Orthopedico Rizzoli in osteosarcoma and malignant fibrous histiocytoma. In: Jacquillat C, Weil M, Khayat D, editors. Neoadjuvant Chemotherapy, vol. 169. John Libbey Eurotext, 1988: 541–4.Google Scholar
  120. 120.
    Rosen G, Caparros B, Huvos AG et al. Preoperative chemotherapy for osteosarcoma. Selection of postoperative adjuvant chemotherapy based on response of primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–39.PubMedGoogle Scholar
  121. 121.
    Meyers PA, Heller G, Healy J et al. Chemotherapy for non-metastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5–15.PubMedGoogle Scholar
  122. 122.
    Winkler K, Bielack SS, Delling G et al. Treatment of osteosarcoma: experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat Res. 1993;62:269–77.PubMedGoogle Scholar
  123. 123.
    Bacci G, Picci P, Ferrari S et al. Primary chemotherapy and delayed surgery for non-metastatic osteosarcoma of the extremities: results of 164 patients preoperatively treated with high-dose methotrexate, followed by cisplatinum and Adriamycin. Cancer. 1993;72:3227–38.PubMedGoogle Scholar
  124. 124.
    Bacci G, Picci P Avella M et al. Effect of intraarterial versus intravenous cisplatin in addition to systemic Adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities. J Chemother. 1992;4:189–95.PubMedGoogle Scholar
  125. 125.
    Epelman S, Seibel N, Melaragno R et al. Treatment of newly diagnosed high-grade osteosarcoma with ifosfamide, Adriamycin and cisplatin without high dose methotrexate. Proc Am Soc Clin Oncol. 1995;14:1399a.Google Scholar
  126. 126.
    Benjamin RS, Patel SR, Armen CH et al. The value of ifosfamide in postoperative neoadjuvant chemotherapy of osteosarcoma. Proc Am Soc Clin Oncol. 1995;14:1690a.Google Scholar
  127. 127.
    Provisor AJ, Ettinger LJ, Nachman JB et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol. 1997;15:76–84.PubMedGoogle Scholar
  128. 128.
    Le Cesne A, Derlord JP Le Deley MC et al. Localized osteosarcoma in adults: the experience of the Institut Gustave Roussy. Proc Am Soc Clin Oncol. 1998;17:1963a.Google Scholar
  129. 129.
    Miser J, Arndt C, Smithson W et al Long term follow-up of high grade osteosarcoma treated with preoperative ifosfamide, adriamycin and high dose methotrexate with cisplatin added postop for poor responders. Proc Am Soc Clin Oncol. 1998;17:2054a.Google Scholar
  130. 130.
    Bacci G, Ferrari S, Mercuri M et al. Neoadjuvant chemotherapy for extremity osteosarcoma. Preliminary results of the Rizzoli’s 4th study. Acta Oncol. 1998;37: 41–8.PubMedGoogle Scholar
  131. 131.
    Meyers PA, Gorlick R, Heller G et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering T-12 protocol. J Clin Oncol. 1998;16:2452–8.PubMedGoogle Scholar
  132. 132.
    Fuchs N, Bielack SS, Epler D et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893–9.CrossRefPubMedGoogle Scholar
  133. 133.
    Chuang VP, Wallace S, Benjamin RS et al. The therapy of osteosarcoma by intraarterial cisplatinum and limb preservation. Cardiovasc Intervent Radiol. 1981;4:229–35.PubMedGoogle Scholar
  134. 134.
    Bacci G, Picci P, Orlandi M et al. Prognostic value of serum alkaline phosphatase in osteosarcoma. Tumori. 1987;73:331–6.PubMedGoogle Scholar
  135. 135.
    Bacci G, Picci P, Ferrari S et al. Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy. Cancer. 1993;71:1224–30.PubMedGoogle Scholar
  136. 136.
    Smith J, Heela RT, Huvos AG et al. Radiographic changes in primary osteogenic sarcoma following intensive chemotherapy. Radiology. 1982;145:355–60.Google Scholar
  137. 137.
    Chuang VP, Benjamin R, Jaffe N et al. Radiographic and angiographic changes in osteosarcoma after intraarterial chemotherapy. Am J Roentgenol. 1982;139:1065–9.Google Scholar
  138. 138.
    Van der Woude HJ, Bloem JL, Hogendoorn PCW. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing’s sarcoma: review of current imaging modalities. Skeletal Radiol. 1988;27:57–71.Google Scholar
  139. 139.
    Linder NJ, Scarborough MT, Spanier SS et al. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumor necrosis, and patient survival. J Cancer Res Clin Oncol. 1998;124:575–80.Google Scholar
  140. 140.
    Carrasco CH, Charnsangavej C, Raymond KA et al. Osteosarcoma: angiographic assessment of response to preoperative chemotherapy. Radiology. 1989;10: 839–42.Google Scholar
  141. 141.
    Carrasco CH. Angiography of osteosarcoma. Hematol/Oncol Clin N Am. 1995;9:627–32.Google Scholar
  142. 142.
    Rosen G, Loren GJ, Brien EW et al. Serial thallium-201 scintigraphy in osteosarcoma: correlation with tumor necrosis after preoperative chemotherapy. Clin Orthop Rel Res. 1993;293:302–6.Google Scholar
  143. 143.
    Lang P, Grampp S, Vahlensieck M et al. Primary bone tumors: value of MR angiography for preoperative planning and monitoring response to chemotherapy. Am J Roentgenol. 1995; 165:135–42.Google Scholar
  144. 144.
    Imbriaco M, Yeh SDJ, Yeung H et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer. 1997;80:1507–12.CrossRefPubMedGoogle Scholar
  145. 145.
    Kunisada T, Ozaki T, Kawai A et al. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy. Angiography compared with thallium-201 scintigraphy. Cancer. 1999;86:949–56.CrossRefPubMedGoogle Scholar
  146. 146.
    Huvos AG, Rosen G, Marcove R. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement. Arch Pathol Lab Med. 1977;101:14–18.PubMedGoogle Scholar
  147. 147.
    Picci P, Bacci G, Campanacci M et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and non-viable tumor. Cancer. 1985;56:1515–21.PubMedGoogle Scholar
  148. 148.
    Raymond AK, Chawla SP, Carrasco CH et al. Osteosarcoma chemotherapy effect: a prognostic factor. Sem Diagnos Pathol. 1987;4:212–36.Google Scholar
  149. 149.
    Raymond AK, Simms W, Ayala AG. Osteosarcoma: specimen management following primary chemotherapy. Hematol/Oncol Clin N Am. 1995;9:841–67.Google Scholar
  150. 150.
    Glasser DB, Lane JM, Huvos AG et al. Survival, prog-nosis, and therapeutic response in osteogenic sarcoma. Cancer. 1992;69:698–708.PubMedGoogle Scholar
  151. 151.
    Goorin A, Schwartzentruber D, Gieser P et al. No evidence for improved event free survival with presurgical chemotherapy for non-metastatic extremity osteogenic sarcoma: preliminary results of a randomized Pediatric Oncology Group trial (8651, an update). Med Ped Oncol. 1996;27:263.Google Scholar
  152. 152.
    Stewart DJ, Benjamin RS, Zimmerman S et al. Clinical pharmacology of intraarterial cis-diammine dichloroplatinum (II). Cancer Res. 1983;43:917–20.PubMedGoogle Scholar
  153. 153.
    Jaffe N, Knapp J, Chuang VP et al. Osteosarcoma: intraarterial treatment of the primary tumor with cisdiammine dichloroplatinum II (CDP). Angiographic, pathologic and pharmacologic studies. Cancer. 1983; 51:402–7.PubMedGoogle Scholar
  154. 154.
    Bielack SS, Erttmann R, Looft G et al. Platinum disposition after intraarterial and intravenous infusion of cisplatinum for osteosarcoma. Cancer Chemother Pharmacol. 1989;24:376–80.CrossRefPubMedGoogle Scholar
  155. 155.
    Eilber FR, Giuliano AE, Eckhardt J et al. A randomized prospective trial of adjuvant chemotherapy for osteosarcoma. In: Salmon S, editor. Adjuvant Therapy of Cancer, vol. V New York: Grune & Stratton; 1987: 691–9.Google Scholar
  156. 156.
    Denton JW, Dunham WK, Salter M et al. Preoperative regional chemotherapy and rapid fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet. 1984;158:545–51.PubMedGoogle Scholar
  157. 157.
    Goodnight JE, Bargar WL, Voegeli T et al. Limb sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy. Am J Surg. 1985;150:109–13.CrossRefPubMedGoogle Scholar
  158. 158.
    Jaffe N, Raymond AK, Ayala A et al. Effect of cumulative courses of intraarterial cis-diammine-dichloroplatinum II on the primary tumor in pediatric osteosarcoma. Cancer. 1989;63:63–7.PubMedGoogle Scholar
  159. 159.
    Jaffe N, Robertson R, Ayala A et al. Comparison of intraarterial cis-diamminedichloroplatinum II with high dose methotrexate and citrovorum factor in the treatment of primary osteosarcoma. J Clin Oncol. 1985;3:1101–4.PubMedGoogle Scholar
  160. 160.
    Benjamin RS, Chawla SP, Carrasco C et al. Arterial infusion in the treatment of osteosarcoma. In: Ryan JR, Baker LO, editors. Recent Concepts in Sarcoma Treatment. Boston: Kluwer; 1988;269–74.Google Scholar
  161. 161.
    Benjamin RS. Regional chemotherapy for osteosarcoma. Semin Oncol. 1989;16:323–7.PubMedGoogle Scholar
  162. 162.
    Benjamin RS, Raymond AK, Carrasco CH et al. Primary chemotherapy of osteosarcoma of the extremities with systemic adriamycin and intraarterial cisplatinum. Proc Am Soc Clin Oncol. 1989;8:322.Google Scholar
  163. 163.
    Bacci G, Springfield D, Capanna R et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity. Clin Orthop. 1987;224:268–76.PubMedGoogle Scholar
  164. 164.
    Picci P, Bacci G, Caparros R et al. Neoadjuvant chemotherapy for localized osteosarcoma of the extremities. Experience related to 112 cases treated between March 1983 and June 1986. In: Salmon S, editor. Adjuvant Therapy of Cancer, vol. V. New York: Grune & Stratton; 1987:711–17.Google Scholar
  165. 165.
    Picci P, Bacci G, Capanna R et al. Neoadjuvant chemotherapy for osteosarcoma — results of a prospective study. In: Ryan JR, Baker LO, editors. Recent Concepts in Sarcoma Treatment. Boston: Kluwer; 1988:291–5.Google Scholar
  166. 166.
    Picci P, Bacci G, Campanacci M et al. Neoadjuvant chemotherapy in osteosarcoma: results of a multicentric study in Italy. In: Jacquilla C, Weil M, Khayat D, editors. Neoadjuvant Chemotherapy, vol. 169. John Libbey Eurotext; 1988:509–13.Google Scholar
  167. 167.
    Bacci G, Pacci P, Ruggieri P et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. Cancer. 1990;65:2539–53.PubMedGoogle Scholar
  168. 168.
    Stine KC, Hockenberry MJ, Harrelson J et al. Systemic doxorubicin and intraarterial cisplatinum preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. Cancer. 1989;63:848–53.PubMedGoogle Scholar
  169. 169.
    Malawer MM, Buch R, Reaman G et al. Impact of two cycles of preoperative chemotherapy with intraarterial cisplatinum and intravenous doxorubicin on the choice of surgical procedure for high grade bone sarcomas of the extremities. Clin Orthop Rel Res. 1991;270:214–22.Google Scholar
  170. 170.
    Patel SR, Seong C, Papadopoulos NE et al. Preliminary results of a phase 2 study of cisplatin, ifosfamide and adriamycin with peripheral blood stem cell reinfusions in patients with untreated bone sarcomas with poor prognosis. Proc Am Soc Clin Oncol. 1998;17:1994a.Google Scholar
  171. 171.
    Baldini N, Scotlaudi K, Barbanti-Brodana G et al. Expression of p-glycoprotein in high grade osteosarcoma in relation to clinical outcome. N Engl J Med. 1995;333:1380–5.CrossRefPubMedGoogle Scholar
  172. 172.
    Bieling P, Rehan N, Winkler P et al. Tumor size and prognosis in aggressively treated osteosarcoma. J Clin Oncol. 1996;14:848–58.PubMedGoogle Scholar
  173. 173.
    Feugas O, Guriec N, Babin-Boilletot A et al. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol. 1996;14:467–72.Google Scholar
  174. 174.
    Chan HS, Grogan TM, Haddad G et al. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst. 1997;89:1706–15.PubMedGoogle Scholar
  175. 175.
    Louardo F, Ueda T, Huvos AG et al. P53 and MDM2 alterations in osteosarcoma: correlation with clinicopathologic features and proliferative rate. Cancer. 1997;79:1541–7.Google Scholar
  176. 176.
    Onda M, Matsuda S, Higaki S et al. ErbB-2 expression correlated with poor prognosis for patients with osteosarcoma. Cancer. 1996;77:71–8.CrossRefPubMedGoogle Scholar
  177. 177.
    Gorlick R, Huvos AG, Heller G et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 1999;17:2781–8.PubMedGoogle Scholar
  178. 178.
    Meyers PA, Heller G, Healy JH et al. Osteogenic sarcoma with clinical detectable metastases at initial presentation. J Clin Oncol. 1993;11:449–53.PubMedGoogle Scholar
  179. 179.
    Bacci G, Mercuri M, Briccoli A et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 1997;79:245–54.CrossRefPubMedGoogle Scholar
  180. 180.
    Harris MB, Gieser P, Goorin AM et al. Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group study, J Clin Oncol. 1998;16:3641–8.PubMedGoogle Scholar
  181. 181.
    Bramwell V, Morris D, Ernst S et al. Phase I/II study with the MDR inhibitor INCEL (Bricodar, VX-710) + doxorubicin in anthracycline resistant advanced soft tissue sarcoma (STS). Proc Am Soc Clin Oncol. 1999;18:2094a.Google Scholar
  182. 182.
    DeMetri GD, Fletcher CDM, Mueller E et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci. 1999;96:3951–6.Google Scholar
  183. 183.
    DeMetri GD, Spiegelman B, Fletcher CD et al. Differentiation of liposarcomas in patients treated with the PPAR ligand troglitazone: documentation of biologic activity in myxoid/round cell and pleomorphic subtypes. Proc Am Soc Clin Oncol. 1999;18:2064a.Google Scholar
  184. 184.
    Kappel CC, Velez-Yanguas MC, Hirschfield S, Helman LJ. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res. 1994;54:2803–7.PubMedGoogle Scholar
  185. 185.
    Zumkeller W, Groth O, Commentz J. Regulation of insulin-like growth factors and IGF-binding proteins in bone tumors. Growth Reg. 1996;6:10–15.Google Scholar
  186. 186.
    Helman LJ, Wexler LH. The growth hormone (GH)/IGF-I axis as a potential target for therapy in osteosarcoma. Second Osteosarcoma Research Conference, Bologna, Italy; 1996:A200.Google Scholar
  187. 187.
    Pegram MD, Lipton A, Hayes DF et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185 HER2/neu monoclonal antibody plus cisplatinum in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998;16:2659–71.PubMedGoogle Scholar
  188. 188.
    Chawla SP, Chua VS, Bauer P et al. Role of alfa-interferon in reducing risk of metastasis in patients with poor prognosis osteosarcoma. Proc Am Soc Clin Oncol. 1999;18:2124a.Google Scholar
  189. 189.
    Kleinerman ES. Biologic therapy for osteosarcoma using liposome encapsulated muramyl tripeptide. Hematol/Oncol Clin N Am. 1995;9:927–38.Google Scholar
  190. 190.
    Kleinerman ES, Gano JB, Johnston DA et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93–9.PubMedGoogle Scholar
  191. 191.
    Linehan DC, Browne WB, Lewis JJ. Immunotherapeutic approaches to sarcoma. Semin Surg Oncol. 1999;17:72–7.CrossRefPubMedGoogle Scholar
  192. 192.
    Esartia PT, Deichman TE, Kluchareva VA et al. Allogeneic bone marrow transfusion suppresses development of lung metastases in osteogenic sarcoma patients after radical surgery. Int J Cancer. 1993;54:907–10.PubMedGoogle Scholar
  193. 193.
    Childs RW, Clave E, Tisdale J et al. Successful treatment of metastatic renal cell carcinoma with a nonmyeloblative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol. 1999;17:2044–9.PubMedGoogle Scholar
  194. 194.
    Hunt KK, Feig BW Preclinical experimental therapeutic approaches in soft tissue sarcoma. Semin Surg Oncol. 1999;17:78–82.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Dennis Priebat
  • Martin Malawer

There are no affiliations available

Personalised recommendations